diclofenac has been researched along with imatinib mesylate in 7 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (42.86) | 29.6817 |
2010's | 3 (42.86) | 24.3611 |
2020's | 1 (14.29) | 2.80 |
Authors | Studies |
---|---|
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Cameron, MD; He, Y; Koenig, M; Li, X; Ruiz, CH; Vojkovsky, T | 1 |
D'Andrea, RJ; Frede, A; Groot-Obbink, K; Hughes, TP; Kok, CH; Osborn, M; Saunders, VA; Somogyi, AA; Wang, J; White, DL | 1 |
Bridges, LR; Elbrecht, D; Funk, C; Hickman, JJ; Long, CJ; Martin, C; McAleer, CW; Roth, AB; Rumsey, JW; Sasserath, T; Schnepper, M; Schuler, F; Shuler, ML; Wang, Y | 1 |
Andrade, RJ; Björnsson, ES; Lucena, MI; Medina-Caliz, I | 1 |
7 other study(ies) available for diclofenac and imatinib mesylate
Article | Year |
---|---|
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Cutaneous drug reaction case reports: from the world literature.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Benzamides; Clozapine; Cyclosporine; Diclofenac; Drug Eruptions; Female; Humans; Imatinib Mesylate; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Nimodipine; Paroxetine; Piperazines; Polyethylene Glycols; Prednisolone; Pyrimidines; Recombinant Proteins; Salicylamides; Spironolactone; Thioridazine; Vinblastine; Vinorelbine | 2003 |
Characterization of dasatinib and its structural analogs as CYP3A4 mechanism-based inactivators and the proposed bioactivation pathways.
Topics: Benzamides; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dasatinib; Diclofenac; Enzyme Activation; Enzyme Inhibitors; Glutathione; Humans; Imatinib Mesylate; K562 Cells; Microsomes, Liver; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Spectrometry, Mass, Electrospray Ionization; Thiazoles | 2009 |
Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Diclofenac; Drug Interactions; Humans; Ibuprofen; Imatinib Mesylate; Inhibitory Concentration 50; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Organic Cation Transporter 1; Piperazines; Pyrimidines | 2012 |
Multi-organ system for the evaluation of efficacy and off-target toxicity of anticancer therapeutics.
Topics: Antineoplastic Agents; Cell Proliferation; Cells, Cultured; Diclofenac; Drug Evaluation, Preclinical; Humans; Imatinib Mesylate; Lab-On-A-Chip Devices; Tamoxifen; Verapamil | 2019 |
Setting up criteria for drug-induced autoimmune-like hepatitis through a systematic analysis of published reports.
Topics: Adalimumab; Chemical and Drug Induced Liver Injury; Diclofenac; Female; Hepatitis A; Hepatitis, Autoimmune; Humans; Imatinib Mesylate; Infliximab; Interferons; Methyldopa; Methylprednisolone; Minocycline; Nitrofurantoin | 2022 |